[Experience with empirical treatment of severe acute respiratory syndrome due to coronavirus, genotype IV]
- PMID: 22359870
[Experience with empirical treatment of severe acute respiratory syndrome due to coronavirus, genotype IV]
Abstract
Foreign experience with empirical management of severe acute respiratory syndrome (SARS) due to coronavirus, genotype IV is described. It is indicated that the data on the efficacy of ribavirin with respect to SARS in the patients are contradictory. The efficacy of two chemotherapeutics, i. e. lopinavir and ritonavir used in the SARS foci is confirmed. The drugs are at present applicable all over the world in retrovirus therapy of HIV infected subjects. The search for efficient Russian unspecific medicines for control of SARS is actual.
Similar articles
-
[Antiretroviral drugs in severe acute respiratory syndrome].Presse Med. 2006 Jan;35(1 Pt 2):105-7. doi: 10.1016/s0755-4982(06)74531-6. Presse Med. 2006. PMID: 16462674 Free PMC article. Review. French.
-
Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.Antivir Ther. 2020;25(4):233-239. doi: 10.3851/IMP3362. Antivir Ther. 2020. PMID: 32496210
-
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5. Trials. 2020. PMID: 33081849 Free PMC article. Clinical Trial.
-
Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.J Hosp Infect. 2019 Jan;101(1):42-46. doi: 10.1016/j.jhin.2018.09.005. Epub 2018 Sep 18. J Hosp Infect. 2019. PMID: 30240813 Free PMC article.
-
[Present state of in vitro and in vivo studies on efficacy of medical nonspecific protective agents with respect to genotype IV coronavirus causing severe acute respiratory syndrome].Antibiot Khimioter. 2011;56(9-10):41-6. Antibiot Khimioter. 2011. PMID: 22586904 Review. Russian.
Cited by
-
Anti-SARS-CoV-2 hyperimmune plasma workflow.Transfus Apher Sci. 2020 Oct;59(5):102850. doi: 10.1016/j.transci.2020.102850. Epub 2020 Jun 10. Transfus Apher Sci. 2020. PMID: 32540345 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous